Next, the results related to cardiac functions from the four studies are presented. This includes median
baseline LVEF values, Median LVEF values after 6 cycles of Liposomal Doxorubicin, cardiac events,
and any other important notes from the authors.
Table 3: Summary of changes in cardiac function of test subjects
Study
Cortes, et al
Median Baseline
Median LVEF
LVEF (%)
after 6 cycles (%)
63%
60%
Cardiac Events
A total of 12 patients (17%) experienced predefined cardiac events (an absolute decline in
LVEF ≥10% resulting in final LVEF <50%,
LVEF <40%, or any absolute decline in LVEF
≥20%). 8 out of the 12 patients recovered fully.
No symptomatic events were observed.
Martin, et al
63.5%
59.9%
A total of 8 (16.7%) patients experienced predefined cardiac events. 7 of the 8 patinets
recovered fully. None of the patients experienced
symptomatic cardiac events.
Chia, et al
63%
60%
Three patients experienced an absolute decline in
LVEF of ≥ 15%. 2 of the 3 patients recovered
completely. None of the patients showed clinical
symptoms of cardiac failure
Stckeler, et
al
66.1% (Mean)
62.7% (Mean)
Three patients experienced severe to moderate
LVEF changes. However, none of the patients
were symptomatic